(Q53364786)

13 May 2018

title

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (English)

1 reference

13 May 2018

ESMO Guidelines Committee

main subject

pancreas

0 references

author

12

object named as

ESMO Guidelines Committee

1 reference

13 May 2018

author name string

M Ducreux

1

1 reference

13 May 2018

A Sa Cuhna

2

1 reference

13 May 2018

C Caramella

3

1 reference

13 May 2018

A Hollebecque

4

1 reference

13 May 2018

P Burtin

5

1 reference

13 May 2018

D Goéré

6

1 reference

13 May 2018

T Seufferlein

7

1 reference

13 May 2018

K Haustermans

8

1 reference

13 May 2018

J L Van Laethem

9

1 reference

13 May 2018

T Conroy

10

1 reference

13 May 2018

D Arnold

11

1 reference

13 May 2018

publication date

1 September 2015

1 reference

13 May 2018

published in

Annals of Oncology

1 reference

13 May 2018

volume

26 Suppl 5

1 reference

13 May 2018

page(s)

v56-68

1 reference

13 May 2018

European cancer mortality predictions for the year 2014.

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Occupational exposures and pancreatic cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Risk factors for pancreatic cancer: a summary review of meta-analytical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Pathological and molecular evaluation of pancreatic neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Premalignant cystic neoplasms of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Pathology of pancreatic ductal adenocarcinoma: facts, challenges and future developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Whole genomes redefine the mutational landscape of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Staging of pancreatic adenocarcinoma by imaging studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Preoperative endoscopic ultrasound-guided fine needle aspiration does not impair survival of patients with resected pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the Association Française de Chirurgie.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Laparoscopic versus open distal pancreatectomy for ductal adenocarcinoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Perioperative mortality after pancreatectomy: a risk score to aid decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Pancreaticoduodenectomy following chemoradiotherapy for locally advanced adenocarcinoma of the pancreatic head

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Endoscopic and operative palliation strategies for pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV295

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDV295

1 reference

13 May 2018

1 reference

13 May 2018